Hirofumi Tomita

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design

K. Kario, N. Kitamura, Y. Nakajima, 2020, Diabetes Therapy.